NCT02523469View on ClinicalTrials.gov

ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

January 8, 2016

Primary Completion Date

February 24, 2023

Study Completion Date

February 24, 2023

Conditions
Non-small Cell Lung Cancer
Interventions
BIOLOGICAL

ALT-803

BIOLOGICAL

Nivolumab

Trial Locations (4)

29425

Medical University of South Carolina, Charleston

33331

Cleveland Clinic Florida, Weston

44195

Cleveland Clinic, Cleveland

55455

University of Minnesota, Minneapolis

Sponsors

Collaborators (1)

Altor BioScience
All Listed Sponsors
collaborator

Altor BioScience

INDUSTRY

lead

Medical University of South Carolina

OTHER